Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.

O'Neill AC, Jagannathan JP, Ramaiya NH.

Korean J Radiol. 2017 Jan-Feb;18(1):6-17. doi: 10.3348/kjr.2017.18.1.6. Epub 2017 Jan 5. Review.

2.

Personalized targeted therapy for lung cancer.

Wu K, House L, Liu W, Cho WC.

Int J Mol Sci. 2012;13(9):11471-96. doi: 10.3390/ijms130911471. Epub 2012 Sep 13. Review.

3.

[Targeted therapies in non-small cell lung cancer in 2014].

Leduc C, Besse B.

Rev Mal Respir. 2015 Feb;32(2):182-92. doi: 10.1016/j.rmr.2014.08.014. Epub 2014 Nov 6. Review. French.

PMID:
25704901
4.

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.

Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354. Review.

5.
6.

[Personalized therapy of lung cancer - current standard and future challenges].

Riedel R, Wolf J.

Dtsch Med Wochenschr. 2017 Nov;142(22):1660-1668. doi: 10.1055/s-0043-114486. Epub 2017 Oct 27. German.

PMID:
29078211
7.

Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.

Choi CM, Kim MY, Hwang HJ, Lee JB, Kim WS.

Radiology. 2015 Apr;275(1):272-9. doi: 10.1148/radiol.14140848. Epub 2015 Jan 7.

PMID:
25575117
8.

Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.

Giuliani J, Martelli S, Remo A, Bonetti A.

Tumori. 2015 Jul 24;101(4):e115-7. doi: 10.5301/tj.5000317.

PMID:
25953440
9.

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.

Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F.

Clin Lung Cancer. 2014 May;15(3):173-81. doi: 10.1016/j.cllc.2013.12.002. Epub 2013 Dec 27. Review.

PMID:
24486058
10.

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.

J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. Review.

PMID:
20921461
11.

Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.

Li W, Zhang Z, Guo L, Qiu T, Ling Y, Cao J, Guo H, Zhao H, Li L, Ying J.

Oncotarget. 2016 Feb 16;7(7):8332-40. doi: 10.18632/oncotarget.6671.

12.

A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer.

Kureshi N, Abidi SS, Blouin C.

IEEE J Biomed Health Inform. 2016 Jan;20(1):424-31. doi: 10.1109/JBHI.2014.2377517. Epub 2014 Dec 4.

PMID:
25494516
13.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
14.

Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.

Kim TJ, Lee CT, Jheon SH, Park JS, Chung JH.

Ann Thorac Surg. 2016 Feb;101(2):473-80. doi: 10.1016/j.athoracsur.2015.07.062. Epub 2015 Oct 9.

PMID:
26454747
15.

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

Shea M, Costa DB, Rangachari D.

Ther Adv Respir Dis. 2016 Apr;10(2):113-29. doi: 10.1177/1753465815617871. Epub 2015 Nov 30. Review.

16.

Personalizing therapy with targeted agents in non-small cell lung cancer.

Dienstmann R, Martinez P, Felip E.

Oncotarget. 2011 Mar;2(3):165-77. Review.

17.

Molecular oncology of lung cancer.

Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S.

Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37. doi: 10.1007/s11748-010-0743-3. Epub 2011 Aug 18. Review.

PMID:
21850578
18.

[Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].

Heigener DF, Horn M, Reck M.

Internist (Berl). 2016 Dec;57(12):1243-1249. doi: 10.1007/s00108-016-0121-z. German.

PMID:
27587193
19.

CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.

Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, Fumagalli C, Spitaleri G, Rampinelli C, De Marinis F, Spaggiari L, Bellomi M.

Eur Radiol. 2016 Jan;26(1):32-42. doi: 10.1007/s00330-015-3814-0. Epub 2015 May 9.

PMID:
25956936
20.

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.

Gerber DE, Oxnard GR, Govindan R.

Clin Pharmacol Ther. 2015 May;97(5):447-50. doi: 10.1002/cpt.91. Epub 2015 Apr 3. Review.

Supplemental Content

Support Center